Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

52.32
Delayed Data
As of 3:59pm ET
 -0.15 / -0.29%
Today’s Change
31.38
Today|||52-Week Range
80.11
+39.74%
Year-to-Date
Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?
Mar 23 / Zacks.com - Paid Partner Content
Alnylam's LDL-Lowering Drug Positive in Phase II Study
Mar 20 / Zacks.com - Paid Partner Content
Regenxbio Leads Biotech Movers Ahead of Market's Open
Mar 22 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close52.47
Today’s open51.01
Day’s range50.77 - 53.63
Volume986,456
Average volume (3 months)1,174,968
Market cap$4.5B
Dividend yield--
Data as of 3:59pm ET, 03/27/2017

Growth & Valuation

Earnings growth (last year)-38.84%
Earnings growth (this year)-7.95%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+14.75%
P/E ratioNM
Price/Sales67.96
Price/Book4.90

Competitors

 Today’s
change
Today’s
% change
MNKMallinckrodt Plc+1.24+2.88%
GRFSGrifols SA+0.25+1.39%
OPKOPKO Health Inc+0.29+3.69%
AGNPRAAllergan plc+6.08+0.72%
Data as of 4:02pm ET, 03/27/2017

Financials

Next reporting dateMay 11, 2017
EPS forecast (this quarter)-$1.28
Annual revenue (last year)$47.2M
Annual profit (last year)-$410.1M
Net profit margin-869.63%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs